{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:44:07Z","timestamp":1785800647748,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Changsha Natural Science Foundation of Hunan Provincial of China","award":["kq2208376"],"award-info":[{"award-number":["kq2208376"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54203-x","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T11:54:01Z","timestamp":1779710041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor treating field plus chemotherapy for locally advanced pancreatic adenocarcinoma: An international cost-effectiveness analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Kun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manting","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"3","key":"54203_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74(3), 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"54203_CR2","unstructured":"World Health Organization, Globocan 2022: Lung, Trachea, and bronchus, version 1.1. https:\/\/gco.iarc.fr\/today\/en\/dataviz\/bars-compare-populations?mode=cancer&group_populations=1&populations=160_840&sort_by=value1&types=1&key=total. (Accessed February 8, 2024)."},{"issue":"9791","key":"54203_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent, A. et al. Pancreatic cancer. Lancet 378(9791), 607\u2013620 (2011).","journal-title":"Lancet"},{"issue":"11","key":"54203_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy, T. et al. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34(11), 987\u20131002 (2023).","journal-title":"Ann. Oncol."},{"issue":"18","key":"54203_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369(18), 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"54203_CR6","unstructured":"National comprehensive cancer network clinical practice guidelines in oncology (NCCN Guidelines\u00ae): Pancreatic Adenocarcinoma, Version 2.2025. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf. (Accessed February 3, 2025)."},{"issue":"3","key":"54203_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","volume":"5","author":"PA Philip","year":"2020","unstructured":"Philip, P. A. et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet. Gastroenterol. Hepatol. 5(3), 285\u2013294 (2020).","journal-title":"Lancet. Gastroenterol. Hepatol."},{"issue":"17","key":"54203_CR8","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel, P. et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315(17), 1844\u20131853 (2016).","journal-title":"JAMA"},{"issue":"23","key":"54203_CR9","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23), 2306\u20132316 (2017).","journal-title":"JAMA"},{"issue":"1","key":"54203_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pan.2018.10.004","volume":"19","author":"F Rivera","year":"2019","unstructured":"Rivera, F. et al. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study. Pancreatology 19(1), 64\u201372 (2019).","journal-title":"Pancreatology"},{"issue":"2","key":"54203_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.soncn.2018.03.005","volume":"34","author":"L Benson","year":"2018","unstructured":"Benson, L. Tumor treating fields technology: alternating electric field therapy for the treatment of solid tumors. Semin. Oncol. Nurs. 34(2), 137\u2013150 (2018).","journal-title":"Semin. Oncol. Nurs."},{"key":"54203_CR12","unstructured":"HM Babiker V Picozzi SR Chandana et al. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. J. Clin. Oncol. Jco2500746. (2025)"},{"issue":"1","key":"54203_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau, D. et al. Consolidated health economic evaluation reporting standards 2022 (cheers 2022) statement: updated reporting guidance for health economic evaluations. Value. Health. 25(1), 3\u20139 (2022).","journal-title":"Value. Health."},{"issue":"10","key":"54203_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.6004\/jnccn.2020.7796","volume":"19","author":"D Ding","year":"2021","unstructured":"Ding, D. et al. Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer. J. Natl. Compr. Canc. Netw. 19(10), 1141\u20131147 (2021).","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"54203_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90960-x","volume":"15","author":"R Long","year":"2025","unstructured":"Long, R., Guo, H. & Chen, K. Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China. Sci. Rep. 15(1), 6429 (2025).","journal-title":"Sci. Rep."},{"key":"54203_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.632818","volume":"12","author":"N Li","year":"2021","unstructured":"Li, N. et al. Cost-effectiveness analysis of Olaparib maintenance treatment for germline BRCA-mutated metastatic pancreatic cancer. Front. Pharmacol. 12, 632818 (2021).","journal-title":"Front. Pharmacol."},{"issue":"5","key":"54203_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7070","volume":"13","author":"K Liu","year":"2024","unstructured":"Liu, K. et al. Combination tumor treating fields treatment for patients with metastatic non-small cell lung cancer: a cost-effectiveness analysis. Cancer. Med. 13(5), e7070 (2024).","journal-title":"Cancer. Med."},{"issue":"3","key":"54203_CR18","doi-asserted-by":"publisher","first-page":"417.e1","DOI":"10.1016\/j.clgc.2022.11.014","volume":"21","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y. et al. First-line lenvatinib plus pembrolizumab or everolimus versus sunitinib for advanced renal cell carcinoma: a united states-based cost-effectiveness analysis. Clin. Genitourin. Cancer. 21(3), 417.e1-.e10 (2023).","journal-title":"Clin. Genitourin. Cancer."},{"key":"54203_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.breast.2022.10.010","volume":"66","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: a cost-effectiveness analysis. Breast 66, 191\u2013198 (2022).","journal-title":"Breast"},{"key":"54203_CR20","unstructured":"Centers for Medicare & Medicaid Services. Drug Average Sales Price. Available from: https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files (Accessed Jan, 2025)."},{"key":"54203_CR21","doi-asserted-by":"publisher","first-page":"1044678","DOI":"10.3389\/fimmu.2022.1044678","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y. et al. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a cost-effectiveness analysis. Front. Immunol. 13, 1044678 (2022).","journal-title":"Front. Immunol."},{"issue":"6","key":"54203_CR22","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1007\/s12325-022-02101-9","volume":"39","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y. et al. Pembrolizumab plus chemotherapy as first-line treatment for advanced esophageal cancer: a cost-effectiveness analysis. Adv. Ther. 39(6), 2614\u20132629 (2022).","journal-title":"Adv. Ther."},{"key":"54203_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1103055","volume":"13","author":"K Liu","year":"2022","unstructured":"Liu, K., Zhu, Y. & Zhu, H. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. Front. Immunol. 13, 1103055 (2022).","journal-title":"Front. Immunol."},{"key":"54203_CR24","unstructured":"US Bureau of labor statistics. CPI inflation calculator. Available at: https:\/\/www.bls.gov\/data\/inflation_calculator.htm. (Accessed July, 2023)."},{"issue":"9","key":"54203_CR25","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S1470-2045(23)00344-3","volume":"24","author":"T Leal","year":"2023","unstructured":"Leal, T. et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (lunar): a randomised, open-label, pivotal phase 3 study. Lancet. Oncol. 24(9), 1002\u20131017 (2023).","journal-title":"Lancet. Oncol."},{"issue":"10","key":"54203_CR26","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1080\/13696998.2019.1614933","volume":"22","author":"GF Guzauskas","year":"2019","unstructured":"Guzauskas, G. F. et al. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. J. Med. Econ. 22(10), 1006\u20131013 (2019).","journal-title":"J. Med. Econ."},{"issue":"2","key":"54203_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11060-024-04662-x","volume":"168","author":"Y Xiang","year":"2024","unstructured":"Xiang, Y. et al. Real-world cost- effectiveness analysis: tumor treating fields for newly diagnosed glioblastoma in China. J. Neurooncol. 168(2), 259\u2013267 (2024).","journal-title":"J. Neurooncol."},{"key":"54203_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1276049","volume":"12","author":"Z Pei","year":"2024","unstructured":"Pei, Z., Xiao, N. & Yang, P. Cost-effectiveness analysis of tumor treating fields treatment in chinese patients with metastatic non-small cell lung cancer. Front. Public. Health. 12, 1276049 (2024).","journal-title":"Front. Public. Health."},{"issue":"10","key":"54203_CR29","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2014.58.4904","volume":"33","author":"DA Goldstein","year":"2015","unstructured":"Goldstein, D. A. et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: A United States-based cost-effectiveness analysis. J. Clin. Oncol. 33(10), 1112\u20131118 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"54203_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40425-018-0440-9","volume":"6","author":"B Wu","year":"2018","unstructured":"Wu, B., Zhang, Q. & Sun, J. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. J. Immunother. Cancer. 6(1), 124 (2018).","journal-title":"J. Immunother. Cancer."},{"issue":"2","key":"54203_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille, E. et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull. World. Health. Organ. 93(2), 118\u2013124 (2015).","journal-title":"Bull. World. Health. Organ."},{"issue":"10","key":"54203_CR32","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/liv.15699","volume":"43","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y., Liu, K. & Zhu, H. Immune checkpoint inhibitor for patients with advanced biliary tract cancer: a cost-effectiveness analysis. Liver. Int. 43(10), 2292\u20132301 (2023).","journal-title":"Liver. Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54203-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54203-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54203-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:49:02Z","timestamp":1785797342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54203-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54203"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54203-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors, it does not require the approval of the independent ethics committee.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23903"}}